Q-omics provides the consensus-scored RSRC1 profile across patient tissues and cancer cell-line models. RSRC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RSRC1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RSRC1 protein abundance shows 29,651 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, HNSC, and LSCC as cancer lineages where RSRC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSRC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSRC1 survival associations across molecular data types. RSRC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSRC1 RNA expression–survival associations across cancer types. High RSRC1 expression shows unfavorable associations in UCEC, KICH, LGG and MESO, but favorable associations in UCS and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RSRC1 RNA expression.
This table summarizes RSRC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RSRC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSRC1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, STAD and LUAD. The HNSC box plot shows higher RSRC1 RNA expression in tumor versus normal tissue (log2 FC = +1.466, t-test p < 0.001).
This table shows molecular features associated with RSRC1 in patient tissues and cancer cell lines. In patient samples, RSRC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RSRC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
